Trial · NCT04740931
Results by group1,012
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,012
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | Arm A: Faricimab Q4W (Part 1) | 16.9 | 95% Confidence Interval 15.4 to 18.3 | ETDRS Letters | |
| Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | Arm B: Aflibercept Q4W (Part 1) | 17.3 | 95% Confidence Interval 15.9 to 18.8 | ETDRS Letters | |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 4 | 13.5 | 95% Confidence Interval 12.5 to 14.6 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 4 | 14.3 | 95% Confidence Interval 13.2 to 15.4 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 8 | 15.5 | 95% Confidence Interval 14.4 to 16.7 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 8 | 16.5 | 95% Confidence Interval 15.3 to 17.7 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 12 | 16.9 | 95% Confidence Interval 15.7 to 18.2 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 12 | 17.1 | 95% Confidence Interval 15.8 to 18.4 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 16 | 16.8 | 95% Confidence Interval 15.4 to 18.1 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 16 | 17.5 | 95% Confidence Interval 16.2 to 18.9 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 20 | 17.0 | 95% Confidence Interval 15.6 to 18.3 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 20 | 17.2 | 95% Confidence Interval 15.8 to 18.5 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 24 | 16.9 | 95% Confidence Interval 15.4 to 18.3 | ETDRS Letters |
| Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 24 | 17.3 | 95% Confidence Interval 15.9 to 18.8 | ETDRS Letters |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24 | Arm A: Faricimab Q4W (Part 1) | 56.6 | 95% Confidence Interval 51.7 to 61.5 | Percentage of participants | |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24 | Arm B: Aflibercept Q4W (Part 1) | 58.1 | 95% Confidence Interval 53.3 to 62.9 | Percentage of participants | |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 4 | 41.5 | 95% Confidence Interval 36.7 to 46.3 | Percentage of participants |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 4 | 45.4 | 95% Confidence Interval 40.7 to 50.2 | Percentage of participants |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Arm A: Faricimab Q4W (Part 1) | Week 8 | 51.1 | 95% Confidence Interval 46.3 to 55.9 | Percentage of participants |
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Arm B: Aflibercept Q4W (Part 1) | Week 8 | 53.7 | 95% Confidence Interval 48.9 to 58.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04740931/results